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ORIGINAL ARTICLE
AAV5-miHTT gene therapy demonstrates suppression of
mutant huntingtin aggregation and neuronal dysfunction in a
rat model of Huntington’s disease
J Miniarikova1,2, V Zimmer3,4, R Martier1,2, CC Brouwers1, C Pythoud3,4, K Richetin3,4, M Rey3,4, J Lubelski1, MM Evers1, SJ van Deventer2,
H Petry1, N Déglon3,4 and P Konstantinova1
Huntington’s disease (HD) is a fatal progressive neurodegenerative disorder caused by a mutation in the huntingtin (HTT) gene. To
date, there is no treatment to halt or reverse the course of HD. Lowering of either total or only the mutant HTT expression is
expected to have therapeutic beneﬁt. This can be achieved by engineered micro (mi)RNAs targeting HTT transcripts and delivered
by an adeno-associated viral (AAV) vector. We have previously showed a miHTT construct to induce total HTT knock-down in
Hu128/21 HD mice, while miSNP50T and miSNP67T constructs induced allele-selective HTT knock-down in vitro. In the current
preclinical study, the mechanistic efﬁcacy and gene speciﬁcity of these selected constructs delivered by an AAV serotype 5 (AAV5)
vector was addressed using an acute HD rat model. Our data demonstrated suppression of mutant HTT messenger RNA, which
almost completely prevented mutant HTT aggregate formation, and ultimately resulted in suppression of DARPP-32-associated
neuronal dysfunction. The AAV5-miHTT construct was found to be the most efﬁcient, although AAV5-miSNP50T demonstrated the
anticipated mutant HTT allele selectivity and no passenger strand expression. Ultimately, AAV5-delivered-miRNA-mediated HTT
lowering did not cause activation of microglia or astrocytes suggesting no immune response to the AAV5 vector or therapeutic
precursor sequences. These preclinical results suggest that using gene therapy to knock-down HTT may provide important
therapeutic beneﬁt for HD patients and raised no safety concerns, which supports our ongoing efforts for the development of an
RNA interference-based gene therapy product for HD.
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INTRODUCTION
Huntington’s disease (HD) is a fatal, currently untreatable,
neurodegenerative disorder with a prevalence rate of 1–10 in
100 000 individuals worldwide.1 The presence of 40 and more CAG
triplets in exon 1 of the huntingtin (HTT) gene has been identiﬁed as
a fully penetrant trigger for the neuropathological process, which
usually stretches over decades.2,3 The resultant neuronal death
affects primarily GABAergic medium spiny neurons in the early
stage of HD, as well as neurons in other brain regions in the later
stages.4,5 The CAG expansion is translated into a polyglutamine
(polyQ) tract in the N-terminus of the HTT protein, causing the
mutant HTT to misfold and aggregate.6 Growing evidence suggests
that the mutant HTT disturbs multiple critical cellular pathways and
that its aggregation is a prerequisite to neurodegeneration.
Therefore, clearance of mutant HTT is currently accepted as being
key for HD treatment.7 Notably, Yamamoto et al.8 showed that
conditional blockage of HTT expression after symptom onset results
in clearance of HTT aggregates and behavioral improvements,
suggesting that HD may be partially reversible.
In contrast to other progressive neurodegenerative disorders,
such as Alzheimer’s or Parkinson’s disease, the monogenic nature of
HD allows for the development of disease-modifying therapies that
aim to halt or suppress production of the aberrant HTT. The
discovery of RNA interference (RNAi) in 1998 revolutionized the
progress of therapeutic interventions focusing on gene silencing at
the post-transcriptional level.9 Since then, several groups, including
ours, applied RNAi principles to design artiﬁcial small interfering
(si)RNAs, short hairpin (sh)RNAs or micro (mi)RNAs that bind to the
HTT transcript and reduce its translation.10,11 To circumvent several
challenges regarding the delivery and stable expression of RNAi
products in the central nervous system, many studies have used
viral vectors as delivery vehicles, which can be injected directly into
the brain. reviewed in Kantor et al.,12 Adeno-associated viral (AAV)
vectors are the most common vehicles of choice and a large
number of AAV capsid serotypes provide cell- and tissue- speciﬁc
tropism. reviewed in Srivastava13 For the central nervous system,
studies in rodents and non human primates have shown AAV
serotype 5 (AAV5) to be strong and effective in the brain, making it
an attractive candidate for the RNAi-based gene transfer.14–17 Impor-
tantly, the AAV-delivered-miRNA-based gene therapy approach
comprises continual expression of artiﬁcial miRNAs following a single
administration of an AAV vector, resulting in long-term HTT lowering.
To develop a disease-modifying gene therapy for HD, we have
previously designed several therapeutic miRNAs targeting either
both ‘total’ or preferentially the mutant HTT transcripts
‘allele-selective’ and their HTT knock-down efﬁciency was
addressed in vitro and in the humanized transgenic Hu128/21
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HD mouse model.18 Based on this study, we selected a miHTT
construct that showed the strongest efﬁcacy in vitro and induces a
potent total HTT knock-down in the striatum and cortex of the
Hu128/21 HD mice.18 For the allele-selective HTT knock-down, we
selected the miSNP50T and miSNP67T constructs that showed
strongest efﬁcacy in vitro.
Although several transgenic or knock-in HD animal models have
been established and used for preclinical testing, none completely
recapitulates the neuropathology that occurs in HD patients.19–21
Therefore, a combination of several in vivo preclinical studies is
required to address the necessary treatment outcome and safety
measures for HD before entering the clinic. In respect to the latter,
the present study was designed to evaluate the on-target efﬁcacy of
continuously expressed miHTT, miSNP50T, and miSNP67T constructs
in suppressing the neuropathology associated with HD using an acute
lentiviral (LV) HD rat model. To generate the HD rat model, wild-type
rats were injected intrastriatally with a LV expressing a chimeric
mutant HTT fragment, which is shown to induce local formation of
mutant HTT aggregates followed by severe neuronal dysfunction at
two months post-infection.22 Therefore, this model allowed us to
address the HD treatment response downstream of the mutant HTT
protein in a larger rodent brain. Moreover, the chimeric LV sequence
enabled us to study both total and allele-selective approaches in the
context of mechanistic efﬁcacy and gene speciﬁcity.23
RESULTS
miHTT-155 delivered by an AAV5 vector suppressed mutant HTT
aggregate formation and DARPP-32-associated neuronal
dysfunction in HD rats
To assess distribution, mechanistic efﬁcacy and allele selectivity of
the therapeutic miRNA sequences, we initiated a pilot study in the
acute LV HD rat model using the miHTT construct for the total HTT
knock-down and the miSNP67T construct for the allele-selective
knock-down. Both miHTT and miSNP67T constructs were pre-
viously designed in the engineered mmu-miR-155 precursor,
named miHTT-155 and miSNP67T-155 (Figure 1a). The miHTT and
miSNP67T expression cassettes also contained a sequence
encoding green ﬂuorescent protein (GFP) to assess transduction
efﬁciency (Figure 1b).18
We generated AAV5 viruses carrying the miHTT and miSNP67T
expression cassettes and co-injected each virus bilaterally in the
striatum of rats with a LV vector encoding a chimeric human
mutant HTT sequence (Figures 1b and c). The LV vector consisted
of an 82-long glutamine (82Q) chain fused with the target regions
for the miHTT and miSNP67T constructs, named LV-mtHTT-67T.23
To address the allele-selective potential of the miSNP67T
construct, we included in this study a second LV vector named
LV-mtHTT-67C. The AAV5-miSNP67T-155 expression product
perfectly matches LV-mtHTT-67T transcripts and has one nucleo-
tide mismatch with LV-mtHTT-67C transcripts at the single
nucleotide polymorphism (SNP) rs362307. Therefore, this system
enabled us to test the allele selectivity based on only a single SNP.
The mutant HTT protein that is expressed from both LV vectors is
known to cause HD-like neuronal dysfunction.22
Two months post-injection, rats were euthanized and the brain
tissues were analyzed for AAV5 vector distribution, mature miHTT
expression, on-target silencing efﬁciency measured by mutant
HTT aggregate formation and DARPP-32-associated neuronal
dysfunction. To evaluate AAV5 vector distribution in the HD rat
brain, we performed immunohistochemistry (IHC) against GFP on
the ﬁxed striato-cortical sections (Figure 2a). For all AAV5
constructs, we observed broad striatal with partial cortical GFP
distribution. Consistent with the latter, we observed ~ 1800 times
Figure 1. Design of a proof-of-concept study using the AAV5-miHTT-155 and AAV5-miSNP67T-155 vectors in an acute HD rat model. (a) The
structure and sequence of the engineered mmu-pre-miR-155 precursor used in the study with the highlighted guide strand in pink.
(b) Schematic representation of the AAV5-miHTT-155 and AAV5-miSNP67T-155 expression cassettes; and LV-mtHTT-67C and LV-mtHTT-67T
expressing the chimeric mutant HTT sequences. (c) Bilateral co-injections in the striatum (STR) of rats with LV-mtHTT-67C or LV-mtHTT-67T,
and AAV5-miHTT-155 or AAV5-miSNP67T-155 vectors. The experimental groups and injection sites are outlined.
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more miHTT molecules in the AAV5-miHTT-155-injected rats
compared with the saline control (Figure 2b).
The accumulation of mutant HTT aggregates in the brain is a
hallmark of the HD neuropathological process.7 To validate on-
target silencing efﬁciency of the AAV5-miHTT-155 and AAV5-
miSNP67T-155 expression products, we performed IHC using an
anti-HTT antibody that binds to the mutant HTT (Figure 2c). We
observed signiﬁcantly fewer mutant HTT aggregates in the HD rat
striata injected with the AAV5-miHTT-155 (0.4 × 106 ± 0.2 × 106,
P⩽ 0.0001) or AAV5-miSNP67T-155 viruses (0.8 × 106 ± 0.3 × 106,
P⩽ 0.0001) compared with the saline control (2.4 × 106 ± 0.4 × 106)
( Figure 2d). The AAV5-miSNP67T-155 showed no allele-selectivity
as similarly low counts of mutant HTT aggregates were observed
in both LV-mtHTT-67C- (0.6 × 106 ± 0.2 × 106) and LV-mtHTT-67T-
injected rats compared with the corresponding saline controls.
To address the effect of AAV5-miHTT-155 and AAV5-
miSNP67T-155 treatments on HD-linked neuronal dysfunction,
we stained for dopamine- and cyclic-AMP-regulated phospho-
protein of 32 kDa(DARPP-32), a phosphoprotein widely expressed
in medium spiny neurons.24 Consistent with the low accumulation
of mutant HTT aggregates, we observed a signiﬁcant reduction of
DARPP-32 lesion size two months after AAV5-miHTT-155
(0.19 mm3± 0.11, P⩽ 0.0001) or AAV5-miSNP67T-155 (0.62 mm3
± 0.19, P⩽ 0.0001) treatments compared with the saline control
(1.92 mm3± 0.29) (Figures 2e and f). AAV5-miHTT-155 was again
shown to be the most effective. Moreover, consistent with the
Figure 2. Phenotypic improvement of HD neuropathology following AAV5-miHTT-155 and AAV5-miSNP67T-155 injections in HD rats. (a) IHC
with an anti-GFP antibody showing AAV5 distribution. A representative picture of the right hemisphere is shown and GFP-positive areas are
depicted by a red arrow . (b) miHTT-speciﬁc TaqMan assay to determine miHTT fold change in the striatum of AAV5-miHTT-155 injected
rats compared with the saline-treated rats (n= 4). miHTT values are presented as the distribution plot with the mean of the values following
normalization to U6 levels. (c) IHC with an anti-HTT antibody showing the mutant HTT aggregates. A representative picture of the right
hemisphere is shown and mutant HTT aggregates are represented by a red arrow . (d) Quantiﬁcation of anti-HTT staining shows a
reduction of mutant HTT aggregates induced by AAV5-miHTT-155 and AAV5-miSNP67T-155 vectors in the striatum (n= 5-12). The reduction
(%) of mutant HTT aggregates is relative to the saline control. (e) Quantiﬁcation of DARPP-32 staining shows a reduction in neuronal
dysfunction induced by AAV5-miHTT-155 and AAV5-miSNP67T-155 vectors in the striatum (n= 5-12). The reduction (%) in neuronal
dysfunction is relative to the saline control. (f) IHC against DARPP-32 showing neuronal dysfunction. A representative picture of the right
hemisphere is shown and DARPP-32-negative areas are depicted by a red arrow . All data were analyzed using one-way ANOVA. NS, non-
signiﬁcant, P40.05; *Pp0.05; **Pp0.01; ***Pp0.001; ****P⩽ 0.0001. The values were calculated as a mean± s.d.
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mutant HTT aggregate counts, AAV5-miSNP67T-155 showed no
allele selectivity as demonstrated by a similar DARPP-32 lesion size
in both LV-mtHTT-67C- (0.07 mm3± 0.07) and LV-mtHTT-67T-
injected rats relative to the saline controls. These experiments
enabled us to identify the miHTT guide sequence effectively
targeting HTT, which resulted in a strong suppression of mutant
HTT aggregate formation and neuronal dysfunction at two
months post-injection.
Optimized miHTT-451 and miSNP50T-451 expressed from AAV5
vectors induced the mutant HTT mRNA knock-down in HD rats
Although the engineered mmu-miHTT-155 constructs generates
the favorable miHTT effector sequence and is suitable for pilot
experiments addressing efﬁcacy and distribution, it is not optimal
for clinical studies in humans due to a high risk of immune
response to GFP and possibility of off-target silencing caused by
the passenger strand.18 Previously, we showed that the silencing
efﬁcacy and processing of the miHTT construct are inﬂuenced by
the pre-miHTT precursor.18 We identiﬁed the miHTT-451 precursor
that showed no passenger strand in vivo opposite to the
miHTT-101 and miHTT-135 precursors (Figure 3a). Moreover, the
miHTT-451 construct showed efﬁcacious HTT knock-down and no
signs of toxicity. Therefore, in this study we included the
miHTT-451 precursor for the total HTT knock-down. For the
allele-selective approach, we optimized the miSNP50T construct
designed to preferentially bind to HTT messenger RNA (mRNA)
carrying the U isoform of SNP rs362331, which is associated at
high frequencies with HD.25 This miSNP50T construct, which
exhibits stronger efﬁcacy than miSNP67T in vitro, was not available
when the pilot study was initiated and therefore, it was introduced
at this stage. Moreover, for both constructs the cytomegalovirus
promoter together with GFP was replaced by the strong
cytomegalovirus immediate-early enhancer fused to chicken β-
actin (CAG) promoter, which has been shown to be effective in the
brain.26 The resultant constructs are named miHTT-451 and
miSNP50T-451 (Figure 3b).
To further establish mechanistic efﬁciency, safety, as well as
allele selectivity in vivo, we generated AAV5-miHTT-451 and AAV5-
miSNP50T-451 vectors and co-injected them bilaterally in the
striatum of rats with a LV vector encoding a chimeric mutant HTT
sequence with an 82Q chain and carrying target regions for the
miHTT and miSNP50T constructs, named LV-mtHTT-50T
(Figures 3b and c). In order to address the allele-selective potential
of the miSNP50T construct, we included a second LV vector,
named LV-mtHTT-50C. The AAV5-miSNP50T-451 expression pro-
duct was designed to have one nucleotide mismatch with the LV-
mtHTT-50T transcripts and two nucleotide mismatches with the
LV-mtHTT-50C transcripts. Therefore, this system enabled us to
test the allele selectivity based on only a single SNP. As negative
controls, we included a GFP expressed from the CAG promoter
and saline control. Two months post-injection, rats were
euthanized and the brains were processed to assess on-target
efﬁcacy, HD-like neuronal dysfunction, and immune reaction.
To measure AAV5 vector DNA in striata, we performed real-time
quantitative PCR (qPCR) with primers directed towards the CAG
promoter (Figure 3d). We observed high and comparable vector
DNA in the striatal homogenates from AAV5-GFP-, AAV5-miHTT-
-451- and AAV5-miSNP50T-451-injected rats. Similar to TaqMan
assays (data not shown), we detected a background level of
~ 3000 genome copies in the saline control, which was considered
for calculations of ﬁnal vector DNA. Furthermore, the latter
inversely correlated with the human-speciﬁc HTT mRNA knock-
down from the same tissue homogenate demonstrated by
TaqMan RT-qPCR (Figure 3e). We detected 62.3%± 21.6 HTT
mRNA knock-down in AAV5-miHTT-451- and 81%± 4.3 HTT mRNA
knock-down in AAV5-miSNP50T-451-injected rats as compared
with the saline control. We observed similar HTT mRNA knock-
down by AAV5-miSNP50T-451 in LV-mtHTT-50T-injected rats
compared with LV-mtHTT-50C-injected rats where 65.5%± 9.2
HTT mRNA reduction was detected.
On-target silencing efﬁciency of AAV5-miHTT-451 and AAV5-
miSNP50T-451 correlates with suppression of DARPP-32-
associated neuronal dysfunction in HD rats
To establish the ability of our optimized AAV5-miHTT-451 and
AAV5-miSNP50T-451 vectors to suppress formation of mutant HTT
aggregates, we analyzed striato-cortical sections by IHC using an
anti-HTT antibody (Figure 4a). Here, in the AAV5-miHTT-451-
injected rats almost no detectable mutant HTT aggregates were
observed (843 ± 359, P⩽ 0.0001), whereas the aggregates were
abundant in the GFP (3.6x104 ± 2.9x104) and saline
(4.4x104 ± 2x104) controls (Figure 4b). Based on the number of
mutant HTT aggregates, AAV5-miSNP50T-451 showed stronger
silencing of the matched LV-mtHTT-50T expression product
(1x104 ± 0.8x104, P⩽ 0.001) compared with the mismatched
LV-mtHTT-50C (4.5x104 ± 2.6x104), suggesting allele-selective
potential.
During development of symptomatic HD, the appearance of
mutant HTT aggregates precedes the death of medium spiny
neurons located in the striatum.22 Therefore, we addressed the
potential of our AAV5-miHTT-451 and AAV5-miSNP50T-451
vectors to suppress DARPP-32-associated neuronal dysfunction
by performing IHC against DARPP-32 (Figures 4c and d).
Consistent with lowering of mutant HTT aggregates, AAV5-
miHTT-451 (0.02 mm3± 0.03, P⩽ 0.0001) and AAV5-
miSNP50T-451 (0.12 mm3± 0.04, P⩽ 0.0001) treatments
signiﬁcantly suppressed the partial striatal lesion induced by the
LV-mtHTT-SNP50T expression product compared with the GFP
(0.92 mm3± 0.39) and saline controls (1.09 mm3± 0.31). In con-
trast, AAV5-miSNP50T-451 treatment did not show strong reduc-
tion in the size of DARPP-32 lesions in LV-mtHTT-SNP50C-injected
rats (0.96 mm3± 0.29), demonstrating allele selectivity.
AAV5 viruses delivering the miHTT-451 or miSNP50T-451
precursors did not induce an overt immune response via GFAP
and Iba1 activation
Although AAV-based gene therapy is an attractive approach for
the delivery of gene products, such as therapeutic miRNAs, and
overall has demonstrated low toxicity to date, activation of the
immune response should be addressed for each therapeutic
candidate in a given target tissue. To evaluate the immune
response to our AAV5 vectors expressing therapeutic miRNA
precursors in the brain, we analyzed the activation of microglia
and inﬁltration of astrocytes in the injected areas by IHC using an
anti-ionized calcium-binding adapter molecule 1 (Iba1) and anti-
glial ﬁbrillary acidic protein (GFAP) antibody, respectively
(Figures 5a and b). We found similar levels of immunoreactivity
in AAV5-miHTT-451- and AAV5-miSNP50T-451-treated rats com-
pared to the saline control, indicating no apparent activation of
immune reaction via microglia and astrocytes.
AAV5-miHTT-451 and miSNP50T-451 constructs do not generate a
passenger strand in vivo
Previously, we showed that the miHTT-451 construct does not
generate a passenger strand and is not toxic probably due to
higher speciﬁcity in vivo (Figure 6a).18 The absence of the
passenger strand from the miR-451 scaffold provides a better
safety proﬁle for therapeutic shRNAs or miRNAs since it reduces
the chance for off-target suppression of other genes by the
passenger strand.18,27,28 To establish the absence of a passenger
strand for the miSNP50T-451 construct in vivo, we analyzed the
processing patterns in the striatum of AAV5-miSNP50T-451-
injected rats by next-generation sequencing. We observed
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consistent processing patterns between the analyzed samples
(Figure 6b). The most abundant reads were 23 nucleotides long
and belonged to the miSNP50T guide strand (Figure 6c). We did
not observe any reads belonging to the passenger strand,
conﬁrming the absence of a passenger strand associated with
the miR-451 precursor.
Based on this study, we identify the AAV5-miHTT-451 construct
as the most efﬁcient candidate for the gene therapy approach
targeting HTT by showing a robust suppression of crucial HD
pathological features in the rat model of HD.
DISCUSSION
In the current study, we have demonstrated the feasibility of total
and allele-selective HTT silencing induced by therapeutic miRNAs
delivered to the brain. Intracerebral administration of AAV5
vectors delivering the miHTT candidates for total HTT knock-
down or the miSNP50T and miSNP67T candidates for the allele-
selective approach resulted in suppression of mutant HTT
aggregates and prevention of DARPP-32-associated neuronal
dysfunction in rat striata. The AAV5-miHTT-451 construct recapi-
tulated the in vitro observations by demonstrating the strongest
efﬁcacy in vivo.
The LV HD rat model very closely and rapidly reproduces the
critical pathogenic features of HD: the mutant HTT aggregation
and striatal neuronal dysfunction. Although this model does not
permit study of improvement in HD-like behavioral symptoms, it
provides a means to preselect therapeutic candidates to continue
with high-cost preclinical studies in large animals that carry on for
several months to years. Previous studies with shRNAs showed
equivalent silencing efﬁcacy of the chimeric HTT constructs in rats
and HEK-293T cells compared with silencing of the endogenous
full-length human HTT in HD-derived neuronal cultures, suggest-
ing that accessibility of silencing agents to the chimeric HTT
constructs resembles the natural situation.23 Moreover, the rapid
severity of DARPP-32-associated neuronal dysfunction challenges
the read-out efﬁcacy; but on the other hand, it strengthens
conﬁdence in case efﬁcacy is demonstrated.
Figure 3. HTT mRNA knock-down induced by AAV5-miHTT-451 and AAV5-miSNP50T-451 vectors in the striatum of HD rats. (a) The structure
and sequence of the hsa-pre-miR-451a precursor used in this study with the miRBase-predicted guide strand highlighted in pink (www.
mirbase.org). (b) Schematic representation of the AAV5-miHTT-451 and AAV5-miSNP50T-451 expression cassettes; and LV-mtHTT-50C and LV-
mtHTT-50T encoding a chimeric mutant HTT sequence with either C or T isoform of SNP rs362331. (c) Bilateral co-injections in the striatum
(STR) of rats with LV-mtHTT-50C or LV-mtHTT-50T, and AAV5-miHTT-451 or AAV5-miSNP50T-451 vectors. The experimental groups and
injection sites are outlined. (d) qPCR to determine AAV5 genome copies (gc) in the striatum of AAV5-miHTT-451 and AAV5-miSNP50T-451
injected rats (n= 3), two months post-injection. Primers directed to the CAG promoter were used and the gc values were calculated based on
the standard curve and considering the background signal from the negative control. (e) TaqMan qPCR assay shows HTT mRNA knock-down
in the striatum (n= 2-3) induced by the AAV5-miHTT-451 and AAV5-miSNP50T-451 expression products. Human HTT-speciﬁc exon-spanning
primers were used and HTT values were subsequently normalized to GAPDH, an internal control set at 100%. All data were analyzed using
one-way ANOVA. *Pp0.05; **Pp0.01; ***Pp0.001; ****P⩽ 0.0001. The values were calculated as a mean± s.d.
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Most HD patients are heterozygous at the HTT locus and
therefore many studies attempt to target only the mutant HTT.
However, the nature of the HD mutation makes allele-selective
HTT silencing challenging. To distinguish between the mutant and
healthy HTT alleles, most of the therapeutic interventions so far
have focused on targeting the heterozygous HD-associated SNPs
or CAG expansions.23,25,29–33 However, not all HD patients have
the identiﬁed common SNP isoforms linked to HD. Therefore,
more than one product would be needed to fully address the HD
patient population. For instance, one study showed that ﬁve
therapeutic products targeting the isoforms of three different
SNPs are required to treat three-quarters of the United States and
European HD patient populations.31 Moreover, as a personalized
medicine, additional genotyping will be required to identify
suitable HD candidates for a given clinical trial. Furthermore, the
allele selectivity based on targeting the CAG expansions depends
on a difference between the consecutive CAGs located on the
mutant and healthy HTT alleles. Nevertheless, it has not shown to
be more efﬁcacious than the SNP approach, when simultaneously
tested.18,32 Ultimately, the presence of CAG repeats in more than
66 genes increases the chance for off-targeting, making it a less
attractive target for clinical testing.34 Consequently, the allele-
selective approach still faces obstacles to advance into the clinical
development.
In this study, we identiﬁed AAV5-miSNP50T-451 that showed
allele-selective silencing of the HTT allele carrying the T isoform of
SNP rs362331. The ongoing experiments with the Hu128/21 mice
that express full-length human HTT with the U isoform of SNP
rs362331 will provide more insights into efﬁcacy and allele-
selectivity of the AAV5-miSNP50T-451. The AAV5-miSNP67T-155
construct showed no allele-selectivity in vivo. mfold prediction
analysis indicated that the secondary RNA structures of miHTT,
miSNP67T and miSNP50T target sites do not form stable duplexes
(data not shown), supporting their similar accessibility to the
therapeutics. Previously, it has been reported that allele-selective
potential of artiﬁcial miRNAs observed in vitro may not be retained
in vivo.35 In general, miRNA–mRNA interactions are determined by
the sequence composition that inﬂuences the thermodynamics,
such as the melting temperature, of the duplex RNA.36 miSNP67T
binds to 52%-rich GC region, which could enhance the miRNA:
mRNA pairing stability and ultimately contribute to no allele-
selectivity based on a single SNP observed in vivo.
Most HTT lowering strategies intend to suppress both HTT alleles
and the ﬁrst ongoing clinical trial with antisense oligonucleotides
Figure 4. Phenotypic improvement of HD neuropathology following AAV5-miHTT-451 and AAV5-miSNP50T-451 injections in HD rats. (a) IHC
using an anti-HTT antibody showing the mutant HTT aggregates. A representative picture of both hemispheres is shown and the mutant HTT
aggregates are depicted by a red arrow . (b) Quantiﬁcation of anti-HTT staining shows a reduction of mutant HTT aggregates induced by
the AAV5-miHTT-451 and AAV5-miSNP50T-451 treatment in the striatum (n= 10). The reduction (%) of mutant HTT aggregates is relative to
the saline control. (c) Quantiﬁcation of DARPP-32 staining shows reduced neuronal dysfunction following AAV5-miHTT-451 and AAV5-
miSNP50T-451 injections in the striatum (n= 10–18). The reduction (%) in neuronal dysfunction is relative to the saline control. (d) IHC against
DARPP-32 showing neuronal dysfunction. A representative picture of both hemispheres is shown and DARPP-32-negative areas are depicted
by a red arrow . All data were analyzed using one-way ANOVA. *Pp0.05; **Pp0.01; ***Pp0.001; ****P⩽ 0.0001. The values were calculated
as a mean± s.d.
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employs this approach (https://clinicaltrials.gov/). Preclinical studies
using HD animal models and non human primates indicate that
there is a therapeutic window where total HTT knock-down is safe
and yet beneﬁcial for HD patients.37–39 Importantly, this strategy
would provide a treatment for all HD patients independent from
their genotype. In this study, we showed that the miHTT construct
processed from the miR-451 scaffold is able to strongly suppress
mutant HTT aggregation and ultimately dramatically reduce the
generation of striatal lesions at two months post-injection.
Moreover, we did not observe immune reaction to the AAV5-
miHTT-451 vector via astrocytes or microglia activation, suggesting
a favorable safety proﬁle.
Altogether, these data provide strong evidence for the
therapeutic efﬁcacy of the AAV5-miHTT-451 vector by inducing
functional improvements downstream in the HD pathological
process without raising safety concerns in a rodent model of HD.
These promising results support our ongoing efforts for the




Homo sapiens HTT mRNA, complete CDS (gb|L12392.1|HUMHDA) obtained
from http://blast.ncbi.nlm.nih.gov/Blast.cgi, was used to identify target
sequences for the artiﬁcial miHTT targeting exon 1, the miSNP50T
construct binding to the U isoform of SNP rs362331, and the miSNP67T
construct targeting the U isoform of SNP rs362307.
DNA constructs
To generate the miHTT-155 and miSNP67T-155 constructs, their guide
sequences targeting HTT transcripts were embedded into the engineered
murine pre-miR-155 backbone of pcDNA6.2-GW/EmGFP-miR (Invitrogen,
Carlsbad, CA, USA) by annealing complementary oligonucleotides (Qiagen,
Valencia, CA, USA) followed by ligation into the linearized pcDNA6.2
plasmid.18
To generate miHTT-451 and miSNP50T-451 constructs, the guide and
passenger strand sequences were incorporated in the hsa-pri-miR-451a
scaffold. 200 nucleotides long 5′ and 3′ encompassing ﬂanking regions
were included with EcoRV and BamHI restriction sites and the complete
sequences were ordered from GeneArt gene synthesis (Invitrogen). In
Figure 5. No apparent activation of microglia and astrocytes following AAV5-miHTT-451 and AAV5-miSNP50T-451 injections in HD rats. (a) IHC
against Iba1 to show microglial activity. A representative picture of the right hemisphere is shown. (b) IHC against GFAP to show the astrocyte
activity. A representative picture of the right hemisphere is shown.
Figure 6. Next-generation sequencing analysis of the pre-miHTT-451 and pre-miSNP50T-451 processing patterns shows no passenger strand
in vivo. (a) Sequence distribution (%) of reads mapping to pre-miHTT-451 in vivo.18 The predicted guide strand is indicated in red and a
mismatch with the reference sequence in light blue. (b) Sequence distribution (%) of reads mapping to pre-miSNP50T in vivo. The predicted
guide strand is indicated in red and a mismatch with the reference sequence in light blue. (c) The length distribution of reads mapping to the
pre-miSNP50T precursor (n= 2). For the read alignments, up to 3 mismatches with the reference sequence were allowed. Reads represented
with less than 3% were excluded from the ﬁgure.
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these constructs, the cytomegalovirus promoter was replaced by the CAG
promoter (Inovio, Plymouth Meeting, PA).18
AAV5 vector production
AAV5 vectors expressing miHTT, miSNP50T, miSNP67T and GFP were
produced by baculovirus-based AAV production system (uniQure, Amster-
dam, The Netherlands). The artiﬁcial miRNA cassettes were cloned in a
transfer plasmid in order to generate an entry plasmid. The expression
cassettes were inserted in a recombinant baculovirus vector by
homologous recombination and clones were selected by plague puriﬁca-
tion. The recombinant baculovirus containing the cassettes were further
ampliﬁed till the passage 6 and clones screened for the best production
and stability by PCR and qPCR. To generate AAV5, infections with different
recombinant baculoviruses containing the vector genome, the replicon
enzyme and the capsid protein were performed. The cells were lysed 72 h
after infection and the crude lysate was treated with Benzonase
(50 U ml− 1; Merck, Darmstadt, Germany) for 1 h at 37 °C. AAV5 was
puriﬁed on AVB Sepharose column (GE Healthcare, Little Chalfont, UK)
using AKTA Explorer puriﬁcation system (GE Healthcare) and the genome
copy titer was determined by qPCR.
Lentiviral vector production
LVs were produced in HEK-293T cells with the four-plasmid system, as
previously described.40 Human immunodeﬁciency virus type-1 vectors
were pseudotyped with the vesicular stomatitis virus glycoprotein
envelope, concentrated by ultracentrifugation and resuspended in
phosphate-buffered saline (PBS, Gibco, Life Technologies, Zug, Switzer-
land) supplemented with 1% bovine serum albumin (BSA, Sigma-Aldrcich,
Buchs, Switzerland). The viral particle content of each batch was
determined by p24 antigen enzyme-linked immunosorbent assay (p24
ELISA, RETROtek, Kampenhout, Belgium). Viral stocks were stored at
− 80 °C. Lentiviral vectors encoding the mutant HTT fragments were used
at 300 ng of p24. Based on transcriptional start site from the PGK promoter
and the presence of polyA+ signal in the 3′LTR of the lentiviral vector, the
mRNAs expressed from the LV-mtHTT-50T and LV-mtHTT-67 constructs are
expected to be ~ 1993 bp and 2059 bp, respectively.41
Animals
Adult male Sprague Dawley rats (200 g; OFA, Charles River, Oncins, France)
were housed in a temperature-controlled room and maintained on a 12 h
day/night cycle. Food and water were available ad libitum. All experiments
were carried out in accordance with the European Community directive
(86/609/EEC) for the care and use of laboratory animals as well as the Swiss
animal welfare laws under the authorization no. VD 2487 and 2889 from
the Service de la consommation et des affaires vétérinaires du Canton de
Vaud, Switzerland.
Stereotaxic injections
The animals were anesthetized using a solution containing 75 mg kg− 1
ketamine (Ketasol, Graeub, Bern, Switzerland) and 10 mg kg− 1 xylazine
(Rompun, Bayer Health Care, Uznach, Switzerland) administered i.p. The rat
was placed in the stereotaxic frame (model 963 Ultra Precise Small Animal
Stereotaxic Instrument, David Kopf Instruments, Tujunga, CA, USA). Viral
vectors were stereotaxically injected into the striatum of animals through a
34-gauge blunt-tip needle (Phymep, Paris, France) linked to a Hamilton
syringe (Hamilton Medical AG, Bonaduz, Switzerland) by a polyethylene
catheter. The stereotaxic coordinates for an intrastriatal injection were:
0.5 mm rostral to bregma, 3 mm lateral to midline and 5 mm from the skull
surface. For the infections, 300 ng p24 antigen of lentiviral vectors were
mixed with 6.5 × 10E10 gc of AAV5 in 4 μl and injected at 0.2 μl min− 1. The
injections were not performed in a blind manner. The rats received
2 mg ml− 1 acetaminophen (Dafalgan, UPSA, Agen, France) in water for the
3 days following the intervention.
Histology
The rats were euthanized by an overdose of sodium pentobarbital
150 mg kg− 1 (B-Braun Mediacal SA, Sempach, Switzerland) and transcar-
dially perfused at a rate of 20 ml min− 1 with 100 ml of 1x PBS and then
with 300 ml of 4% PFA. Brains were removed and post-ﬁxed by incubation
in 4% PFA for 24 h at 4 °C and cryoprotected by incubation in 20% sucrose
(Sigma-Aldrich, Buchs, Switzerland) in 1x PBS for 24 h and in 30% sucrose
in 1x PBS for 24 h. Brains were frozen on dry ice and then stored at − 80 °C.
For RNA analysis, the animals were euthanized and the brains were snap-
frozen in liquid nitrogen.
25 μm-thick coronal brain sections were cut on a sledge microtome with
a freezing stage at − 30 °C (Leica SM2010R, Biosystems Switzerland,
Nunningen, Switzerland). Sections throughout the striatum were collected
and kept in tubes, as free-ﬂoating sections in anti-freeze solution (25%
glycerol (Sigma-Aldrich, Buchs, Switzerland), 30% Ethylene glycol (Merck,
Nottingham, UK), 25% 1x PBS and 20% nanopure water).
Immunostaining
Free-ﬂoating sections were washed three times, for 10 min each, in
Tris-buffered saline (TBS, 10 mM Tris pH=7.6 and 0.9% NaCl Sigma-Aldrich,
Buchs, Switzerland). Non-speciﬁc peroxidases were inactivated by incuba-
tion in quenching solution (TBS supplemented with 3% H2O2 and 10%
methanol, Sigma-Aldrich, Buchs, Switzerland) for 15 min at room
temperature. Sections were washed twice, for 10 min each, in TBS, and
then for 10 min in TBS-0.1% Triton X-100 (TBST). Sections were blocked by
incubation in Tris-high salt-buffer (THST, 50 mM Tris pH=7.6, 0.5 M Nacl,
0.5% Triton X-100,) for anti-HTT antibody or TBST-5% NGS for DARPP-32
antibody during 1 h at room temperature and were then incubated
overnight at 4 °C in TBST-1% BSA with antibodies. The following primary
antibodies were used: Goat polyclonal anti-HTT antibody (1/1000, Sicgen,
Coimbra, Portugal), rabbit polyclonal anti-DARPP-32 antibody (1/1000, Cell
Signaling Technology Europe, Leiden, The Netherlands), rabbit polyclonal
anti-GFP antibody (1/100 000, Abcam, Cambridge, UK), rabbit polyclonal
anti-IbaI antibody (1/25 000, Wako Chemicals, Richmond, USA) and rabbit
polyclonal anti-GFAP antibody (1/500, Dako, Baar, Switzeland). After
incubation with the primary antibody, the sections were washed three
times, for 10 min each, in TBS and then incubated for 1 h at room
temperature in TBST-1% BSA with secondary antibodies. The following
secondary antibodies were used: biotinylated donkey anti-goat IgG
(1/1000, Jackson, Pennsylvania, USA) and biotinylated goat anti-rabbit
IgG (1/400, Vector Lab Inc, Burlingame, USA). Sections were washed three
times, for 10 min each, in TBST and incubated for 1 h at RT in ABC (Vector
Lab Inc). Samples were washed twice, for 10 min each, in TBS and were
then incubated with nickel chloride and diaminobenzidine (DAB, Vector
Lab Inc) for antibody detection. Sections were mounted on Superfrost
Ultraplus slides. Sections were allowed to dry in a laminar ﬂow hood and
were dehydrated (70% ethanol in nanopure water, 95% ethanol in
nanopure water, 100% ethanol, 100% ethanol and xylene) before
mounting in Eukitt (Kindler GmbH, Freiburg, Germany).
Image acquisition and quantiﬁcation
Images were obtained with a digital camera (3CCD Hitachi HV-F202SCL) on
a slide scanner microscope (×20 objective, Zeiss axioscan Z1). Measure-
ments were made with Image J software (http://rsb.info.nih.gov/ij/, NIH,
Bethesda, USA) for aggregates and Zeiss Zen Lite 2 (blue Edition; Carl Zeiss
AG, Germany) for DARPP32 lesion. An Image J macro was developed to
count the number of aggregates. The aggregates were identiﬁed on the
basis of their intensity relative to the background, their size and their
circularity. The same intensity, size and circularity parameters were used
for all samples.
Quantiﬁcation of mtHTT aggregates and DARPP-32 lesions
The number of mutant HTT aggregates in the striatum was automatically
counted in 1 in 8 sections with analyze particle plugin on ImageJ
(Supplementary Material and Method 1). Cut-off with minimum size and
maximum pixel area size was applied to exclude non-aggregates in the
ROI. The total number of aggregates was estimated by multiplying these
densities by 8. The loss of DARPP-32 expression was analyzed by collecting
digitized images sections (1 in 8 sections separated by 200μm). Lesion
areas in each section were determined as regions poor in DARPP-32
staining relative to the surrounding tissue. The lesion volume for each
animal was quantiﬁed with the following formulae: lesion in mm3 = (mean
size in μm2×number of counted section× inter-section distance)/1 × 10E9.
Means and s.d.’s were calculated for each group. The quantiﬁcations were
performed in a blind manner.
Quantitative real-time PCR
Rat striata were crushed using CryoPrep System (Covaris, Woburn, MA,
USA) and the powder was divided for RNA and DNA analyses. For RNA
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isolation, the striatal powder was homogenized in Trizol using gentleMACS
Dissociator (Miltenyi Biotec) and total RNA was isolated from Trizol
according to the manufacturer’s protocol (Invitrogen). To remove genomic
DNA, RNA was treated with dsDNase (Thermo Scientiﬁc, Waltham, MA,
USA). Quantitative real-time PCR reaction was performed to detect
HTT mRNA knock-down using TaqMan gene expression assays
(Applied Biosystems, Foster City, CA, USA), human HTT
(Hs00918134_m1), rat GAPDH (Rn01462662_g1); and miHTT expression
levels using custom TaqMan microRNA expression assay or U6 snRNA
(001973; Applied Biosystems). The expression level of each gene was
normalized to either endogenous GAPDH or U6 snRNA levels. Fold change/
percentages in HTT mRNA knock-down or miHTT expression were
calculated based on 2^DDCT method (Supplementary Material and
Method 2).
For the genomic DNA isolation, the striatal powder was processed using
DNeasy96 Blood and Tissue kit (Qiagen). qPCR reaction was performed to
detect AAV5 vector titers using a standard line and SYBR Green protocol
(Applied Biosystems). Forward primer sequence: 5′-GAGCCGCAGCCA
TTGC-3′ and reverse primer sequence: 5′-CACAGATTTGGGACAAAGGAAGT
-3′. Based on the standard line, genome copies per microgram DNA were
calculated.
Next-generation sequencing data analysis
The raw sequencing data were produced as previously described.18 Small
RNA raw data sets were analyzed using the CLC Genomics Workbench 6
(Qiagen). All reads containing ambiguity N symbols, reads shorter than 10
nucleotides, longer than 45 nucleotides and reads represented less than 10
times were discarded. The obtained unique small RNA reads were aligned
to the reference sequences of the pre-miHTT and pre-miSNP50T constructs
with a max. of 3 nucleotide mismatches allowed. The percentages of reads
based on the total number of reads matching the reference sequences
were calculated.
Sample sizes, calculations and statistical analysis
Sample sizes of saline n=18, GFP n= 16, AAV5-miHTT-155 n= 18, AAV5-
miHTT-451 n= 16, AAV5-miSNP67T-155 n= 16 and AAV5-miSNP50T-451
n= 16 represent the number of striata injected per experimental group.
The sample size was chosen to consider statistical variability due to
surgical procedure based on previous studies. All experiments involving
animals were performed once. The only exclusion criterion was if a
problem was encountered during the injection procedure. The knock-
down percentages were calculated using the following formula: Knock-
down (%) = [AAV5-miRNA treatment]/[saline treatment] × 100%. Data were
analyzed using one-way ANOVA. *Pp0.05; **Pp0.01; ***Pp0.001;
****P⩽ 0.0001. Differences were considered signiﬁcant when Pp0.05.
The values were calculated as a mean± s.d.
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